Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.47 Bn | 30.53 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.10 Bn | 20.95 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 27.85% |
| 10 | Biocryst Pharmaceuticals | 2.38 Bn | 2.31 Bn | 151.04 Mn | -9.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.15% |
| Dec 31, 2025 | 142.40% |
| Sep 30, 2025 | 48.62% |
| Jun 30, 2025 | 51.66% |
| Mar 31, 2025 | 29.28% |
| Dec 31, 2024 | 45.64% |
| Sep 30, 2024 | 33.03% |
| Jun 30, 2024 | 62.24% |
| Mar 31, 2024 | 4.17% |
| Dec 31, 2023 | 40.59% |
| Sep 30, 2023 | 19.58% |
| Jun 30, 2023 | 15.37% |
| Mar 31, 2023 | -26.84% |
| Dec 31, 2022 | -31.67% |
| Sep 30, 2022 | -5.49% |
| Jun 30, 2022 | -4.25% |
| Mar 31, 2022 | -42.30% |
| Dec 31, 2021 | -10.61% |
| Sep 30, 2021 | 12.74% |
| Jun 30, 2021 | -22.29% |